Skip to content

Antiepileptic pharmacogenomics in children

A real-world cohort study of antiepileptic pharmacogenomics in pediatrics

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050920
Enrollment
Unknown
Registered
2021-09-08
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

case series:None

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of epilepsy based on clinical seizures and EEG results; 2. The type of epilepsy or epilepsy syndrome can be identified; 3. Take antiepileptic drugs to reach the lowest drug dose (such as sodium valproate, 20mg/kg); 4. Regularly take antiepileptic drugs, and maintain the lowest drug dose for more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Contains a variety of seizure types; 2. Long-term use of other types of drugs (such as hormones, immunosuppressants, etc.) while taking antiepileptic drugs; 3. Those who are identified as developmental epileptic encephalopathy (DEE) (currently known DEE-related 96 genes and MECP2, etc.); 4. Identify metabolic epilepsy (GLUT1 gene defect), glycine encephalopathy, etc.; 5. Initial application of multiple antiepileptic drugs, but the efficacy of a single drug cannot be determined; 6. Poor compliance, unable to take medicine regularly.

Design outcomes

Primary

MeasureTime frame
Whole genome sequencing;

Countries

China

Contacts

Public ContactYang Guang

Chinese PLA General Hospital

yangg301@sina.com+86 13810692267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026